BTEC Stock Overview
An exchange traded fund launched by BlackRock Asset Management Ireland Limited.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
iShares IV Public Limited Company - iShares NASDAQ US Biotechnology UCITS ETF Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.86 |
| 52 Week High | US$7.20 |
| 52 Week Low | US$5.25 |
| Beta | 0 |
| 11 Month Change | -2.90% |
| 3 Month Change | 4.18% |
| 1 Year Change | 19.68% |
| 33 Year Change | -3.48% |
| 5 Year Change | 55.15% |
| Change since IPO | 39.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| BTEC | GB Capital Markets | GB Market | |
|---|---|---|---|
| 7D | -3.1% | -0.2% | -0.5% |
| 1Y | 19.7% | 27.4% | 7.9% |
Return vs Industry: BTEC underperformed the UK Capital Markets industry which returned 26.9% over the past year.
Return vs Market: BTEC exceeded the UK Market which returned 7.4% over the past year.
Price Volatility
| BTEC volatility | |
|---|---|
| BTEC Average Weekly Movement | 2.4% |
| Capital Markets Industry Average Movement | 3.9% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.3% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: BTEC has not had significant price volatility in the past 3 months.
Volatility Over Time: BTEC's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | n/a | www.ishares.com/uk/individual/en/products/291450/ |
iShares IV Public Limited Company - iShares NASDAQ US Biotechnology UCITS ETF is an exchange traded fund launched by BlackRock Asset Management Ireland Limited. It is managed by BlackRock Advisors (UK) Limited. The fund invests in the public equity markets of the United States.
iShares IV Public Limited Company - iShares NASDAQ US Biotechnology UCITS ETF Fundamentals Summary
| BTEC fundamental statistics | |
|---|---|
| Market cap | US$530.17m |
| Earnings (TTM) | US$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs BTEC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BTEC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$0 |
| Earnings | US$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did BTEC perform over the long term?
See historical performance and comparison